G
GRAIL
Developing blood tests for early cancer detection high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science
At a glance
- Founded
- 2016
- Headquarters
- Menlo Park, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning GRAIL.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
Sutter Hill Ventures
Bezos Expeditions
GV
Illumina
ARCH Venture Partners- BGBill Gates
Series B and later12 investors entered at this stage
Sequoia- GSGenuity Science
- 6C6 Dimensions Capital
Hillhouse Capital- CIChina Merchant Securities International
- HCHuangPu River Capital
CPP Investments- AGAlly Bridge Group
- ICIndustrial and Commercial Bank of China
- BCBlue Pool Capital
- JJJohnson & Johnson
- CICRF Investment
Source: Dealroom Talent Intelligence.
Alumni founders
Former GRAIL employees who went on to found companies, sorted by Dealroom signal score.
CECellanomeEst. 2020
ANAria NetworksEst. 2025
Subhachandra ChandraUnited States
XTXaira TherapeuticsEst. 2023
Vik BajajUnited States
BABeacons AIEst. 2019
Jesse ZhangUnited StatesGlobal footprint
team presence
across markets
Patents
181 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about GRAIL on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GRAIL on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
